Hill Street Announces Definitive Agreement to Acquire Assets of Lexaria Canpharm, and Closing of Private Placement

Companies to continue both operational and research partnership for ten years

Toronto, Ontario–(Newsfile Corp. – November 18, 2020) – Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”) today announces it has signed a definitive agreement to acquire the primary assets of Lexaria Canpharm, the cannabis-related division of Lexaria Bioscience Inc. (CSE: LXX). Thisacquisition provides Hill Street with the exclusive rights in perpetuity to use Lexaria’s ground-breaking DehydraTECHTM patent portfolio on a global basis to make any type of products containing THC and other psychoactive cannabinoids. In addition, the agreement expands Hill Street’s license with Lexaria HempCo to make products containing CBD on a global basis for ten years.

Terms of the acquisition

  • Total consideration of $3.85 million, including $350K in cash upon closing and future payments of $2.0 million.
  • Hill Street will issue Lexaria Bioscience a total of $1.5MM worth of Common Shares in the capital of the Company in three equal installments with the first tranche issuable on closing. The first tranche will be issued at a price of $0.0829 per share, which is equal to the 10-day volume weighted average closing price of the Common Shares on the TSX Venture Exchange on the date hereof. All successive issuances shall be issued at the greater of (A) the 10-day volume weighted average closing price of the Common Shares on the TSX Venture Exchange on such payment date; and (B) $0.0829;

With over sixty patents for DehydraTECHTM either issued or pending, this transaction positions Hill Street to expand its strategy of producing ingredients for Cannabis 2.0 products, allowing the Company to take advantage of growing demand for “quick onset and duration” recreational cannabis edibles and topicals. This transaction will allow Hill Street to expand its addressable market to every country in the world where cannabis is either medicinally or recreationally legal. Lexaria’s Intellectual Property converts perishable cannabis products such as oils and extracts into shelf stable powders. Hill Street will manufacture these powders for sale to licensed cannabis processors at its own facility as well as sub-license the technology to licensed manufacturers globally. Shelf stable cannabis powders are the ideal ingredients upon which to build world class Cannabis 2.0 brands, including beverages, edibles, and topicals. The DehydraTECHTM processes are well researched, market validated, and well protected through multiple patents, and will continue to improve as Lexaria continues its research.

Completion of the transaction is subject to the approval of the TSX Venture Exchange.

“With this transaction, we are building on an already strong partnership with Lexaria. We are gaining full ownership of the joint manufacturing partnership we created last year, and positioning Hill Street to become an early leader in the global market for cannabis 2.0 ingredients and products. Our cannabis processing facility is designed specifically to produce shelf stable ingredients using DehydraTECHTM for the Cannabis 2.0 market,” said Terry Donnelly, Chairman & CEO of Hill Street. “With a significant portion of the consideration in shares and future payments, this transaction demonstrates Lexaria’s faith in Hill Street to unlock the value of their innovations for their shareholders based on our success.”

Hill Street’s team is executing a new and exciting strategy in the cannabis sector, designed to take advantage of the Cannabis 2.0 market and enhanced consumer expectations,” stated Chris Bunka, Chairman & CEO of Lexaria Bioscience. “Their deep expertise in consumer goods will allow consumers to experience Lexaria’s innovations through the highest performance products available in the Cannabis 2.0 sector. Lexaria’s focus remains on creating the greatest innovations possible in drug delivery in the diverse sectors of nicotine, cannabinoids, and antivirals for both the therapeutic and pharmaceutical industries. Innovations in drug delivery in the pharmaceutical industry represents a massive global opportunity for Lexaria, and this transaction with Hill Street assists our ability to focus, while providing our shareholders with a significant carried interest in a fast growing startup well positioned for success in the cannabis 2.0 market.”

Ongoing Relationship with Lexaria Bioscience

Hill Street will continue to partner with Lexaria Biosciences in certain markets for Cannabis 2.0 products using Lexaria’s patented DehydraTECHTMprocess by providing a license back to Lexaria to produce therapeutic and medicinal products containing THC. Upon full payment of the consideration for the transaction, Hill Street will earn royalties from the sales of Lexaria’s products using the Canpharm licenses. Further, Hill Street will continue to have access to Lexaria’s leading edge research capabilities into the use of DehydraTECHTM with cannabinoid products. The DehydraTECHTM processes provide for rapid onset and offset of the effects of cannabinoids and allows manufacturers to create shelf stable products from cannabis extracts. Hill Street has begun development of a facility in Mississauga where the cannabis ingredients will be manufactured. The Company expects the facility to be operational in 2021, pending Health Canada and other regulatory approvals.

Completion of Private Placement

The Company also announces that it has completed its previously announced non-brokered private placement of units (“Units“), for aggregate gross proceeds of $850,950. Each Unit was issued at a price of $0.05 and is comprised of one common share, and one whole warrant (“Warrant“), with each warrant entitling the holder to acquire one Common Share at an exercise price of $0.13 for a period of two years from the date of closing, subject to acceleration. In connection with the private placement the Company paid finders fees of $2,000 to Jamie Salter, $2,025 to Victor Godinho, both arm’s length parties to the Company.

About Hill Street Beverage Company Inc. (TSXV: BEER)

Hill Street Beverage Company is a leading and award-winning company focused on alcohol-free beer, wine, and adult-format beverages. Hill Street’s brands include Hill Street Craft Brewed Lager, Vin(Zero) and Vintense wines, and have won numerous medals and accolades around the world. Hill Avenue Cannabis, the Company’s wholly-owned subsidiary, will produce and sell cannabis-infused adult beverages and other cannabis products with expected distribution at licensed outlets in 2020. Check out Hill Street’s award-winning line-up and order product to be delivered straight to your home at www.hillstreetbeverages.com.

Cannabis-infused Adult Beverages

In October 2020, Hill Street announced the launch of its (V)ia SPRIZA Cannabis Infused Beverages brand, to be manufactured in a partnership with Molecule Inc., a licensed producer of cannabis beverages. The Company anticipates that these beverages will be available through licensed cannabis retailers in Ontario in December 2020, with a planned roll out to major markets nationally in 2021. The Company continues to explore the development of additional Cannabis 2.0 products which would be accretive to its business.

For further information:
Terry Donnelly, Chairman and CEO, Hill Street Beverage Company Inc.,
terry@hillstreetbevco.com, (416) 543-4904;

Follow Hill Street on Twitter https://twitter.com/hillstreetbevco

and on Facebook http://facebook.com/hillstreetbevco


Statements in this press release may contain forward-looking information. Any statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expects”, and similar expressions. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances, such as future availability of capital on favourable terms, may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement. The forward-looking statements contained in this press release are made as of the date of this press release. The Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as required by securities law.

Not for dissemination in the United States of America.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.